MILESTONE
BUSINESS
Torrent Pharma FYQ1 PAT rises 3.3% as JB integration costs & higher finance charges weigh on earnings
Revenue from operations surged 55% to ₹4,921 crore
Pulse Bharat · Why it matters
Read the original at The Hindu BusinessLine ↗
Torrent Pharma's profit growth reflects integration challenges and financial costs affecting the Indian pharmaceutical sector's earnings.